Clinical trials: Post Myocardial Infarction
Coronary Artery Disease, Stable Angina
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data…
- Conditions
- Coronary Artery Disease, Stable Angina, Ischemia, Acute Coronary Syndrome
- Trial name
- NCT02871622
- Testing
- BioMatrix AlphaTM
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Biosensors Europe SA
Acute Myocardial Infarction, Pacing Therapy
Post-Myocardial Infarction Remodeling Prevention Therapy
The purpose of this study is to demonstrate the feasibility of pacing as a therapy to prevent adverse remodeling of the myocardium following an acute myocardial infarction (MI) in patients at highest risk for adverse myocardial…
- Conditions
- Acute Myocardial Infarction, Pacing Therapy, Cardiac Remodeling, Heart Failure
- Trial name
- PRomPT (NCT01213251)
- Testing
- Single Site Pacing, Dual Site Pacing
- Where
- 26 sites in United States, Denmark and 5 more
- Volunteers
- 129 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Deep Vein Thrombosis, Atrial Fibrillation
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device
Comparison of capillary whole blood INR determined by LumiraDx Instrument to venous plasma INR determined by laboratory reference method (IL ACL ELITE PRO) for method comparison and assessment of accuracy and bias by regression…
- Conditions
- Deep Vein Thrombosis, Atrial Fibrillation, Post-Myocardial Infarction Syndrome, Pulmonary Embolism
- Trial name
- OPTIMAL (NCT03682419)
- Testing
- VKA Patients, Non-VKA Patients
- Where
- 3 sites in United Kingdom
- Volunteers
- 420 people
- Sponsor
- LumiraDx UK Limited
Myocardial Infarction
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
- Trial name
- NCT00414609
- Testing
- Aliskiren
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 820 people
- Sponsor
- Novartis
Congestive Heart Failure
To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction
This study injects a person's own stem cells into heart muscle tissue after a person has one or more heart attacks. The purpose of the study is whether the stem cells will improve a patient's heart performance.
- Trial name
- MARVEL (NCT00526253)
- Testing
- MyoCell, Hypothermosol
- Where
- 33 sites in United States
- Volunteers
- 170 people
- Sponsor
- Bioheart, Inc.
Non ST-elevation Myocardial Infarction
Brilinta Taiwan Post Approval Safety Study
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the…
- Trial name
- NCT02406248
- Testing
- Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
- Where
- 13 sites in Taiwan
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Myocardial Infarction
A Study to Evaluate the Impact of Long-term Digital Education vs Standard of Care on LDL-C Levels in Post Myocardial Infarction Patients
The purpose of this study was to demonstrate the impact of digital education on the cardiovascular risk factors in post-Myocardial Infarction patients and to generate evidence for broad implementation of the proposed education…
- Trial name
- DEDUCA-CZ (NCT06548555)
- Testing
- systematic educational intervention
- Where
- 5 sites in Czechia
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction
MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction)
The objective of the present study is to establish the safety and efficacy of MiSaver® Stem Cell Treatment After a Heart Attack (Acute Myocardial Infarction)
- Trial name
- MiSaver® (NCT04050163)
- Testing
- MiSaver®
- Where
- 2 sites in Taiwan
- Volunteers
- 11 people
- Sponsor
- Honya Medical Inc
Ventricular Dysfunction, Myocardial Infarction
Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone
The object of this open-labeled, uncontrolled pilot study was to investigate the safety and feasibility of percutaneously transplanting autologous bone marrow (ABM) cells into the myocardium using the helical needle…
- Trial name
- TABMMI (NCT00507468)
- Testing
- Transendocaridal Transplantation of Autologous Bone Marrow
- Where
- 2 sites in Argentina
- Volunteers
- 20 people
- Sponsor
- BioCardia, Inc.
Myocardial Infarction
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community…
- Trial name
- NCT00623623
- Testing
- primary PCI, enoxaparin, catheterisation
- Where
- 201 sites in Austria, Belgium and 14 more
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim